Abstract
Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb / IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb / IIIa blockade when given in conjunction with heparin, chronic oral GPIIb / IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
Keywords: antiplatelet therapies, cerebrovascular diseases, atherosclerosis, intravascular thrombus, clopidogrel, platelet gpIIb/IIIa antagonists, thromboembolic disorders, thrombotic disorders
Current Pharmaceutical Design
Title: Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Volume: 9 Issue: 28
Author(s): Shaker A. Mousa
Affiliation:
Keywords: antiplatelet therapies, cerebrovascular diseases, atherosclerosis, intravascular thrombus, clopidogrel, platelet gpIIb/IIIa antagonists, thromboembolic disorders, thrombotic disorders
Abstract: Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb / IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb / IIIa blockade when given in conjunction with heparin, chronic oral GPIIb / IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
Export Options
About this article
Cite this article as:
Mousa A. Shaker, Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond, Current Pharmaceutical Design 2003; 9 (28) . https://dx.doi.org/10.2174/1381612033453893
DOI https://dx.doi.org/10.2174/1381612033453893 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart
Current Cardiology Reviews Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?
Current Pharmaceutical Design Role of Endothelial Nitric Oxide in Cerebrovascular Regulation
Current Pharmaceutical Biotechnology Clozapine Safety, 40 Years Later
Current Drug Safety Gene Modified Cell Transplantation for Vascular Regeneration
Current Gene Therapy Di'ao Xinxuekang: Therapeutic Potential in Cardiovascular Diseases
Current Molecular Pharmacology Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Innate Inflammatory Responses in Stroke: Mechanisms and Potential Therapeutic Targets
Current Medicinal Chemistry Opposite Effects of Two-Derived Antioxidants from Physalis pubescens L. on Hepatocellular Carcinoma Cell Line Malhavu
Current Pharmaceutical Biotechnology Ca2+ Signalling in Damaged Endothelium: Do Connexin Hemichannels Aid in Filling the Gap?
Current Drug Therapy Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase
Medicinal Chemistry The Relationship Between Cleft Lip, Maxillary Hypoplasia, Hypoxia and Phenytoin
Current Pharmaceutical Design Selectins as Targets in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Control of Arterial Hypertension: Epidemiological and Economic Challenge
Current Hypertension Reviews Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus
Current Cardiology Reviews Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)